Go Kimura

Tokyo, 1138603, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Deep learning augmented pathological grading and intraductal carcinoma of the prostate signatures improve recurrence prediction after intensity-modulated radiation therapy.

Deep learning augmented pathological grading and intraductal carcinoma of the prostate signatures improve recurrence prediction after intensity-modulated radiation therapy.

Journal: Virchows Archiv : an international journal of pathology

Published: May 18, 2026

Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.

Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.

Journal: IJU case reports

Published: March 23, 2026

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.

Journal: IJU case reports

Published: February 06, 2026

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 18, 2026

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.

Journal: EJNMMI reports

Published: December 31, 2025

Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate.

Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate.

Journal: Pharmaceutics

Published: October 21, 2025

A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.

A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: October 15, 2025

Perceptions and Expectations of Pharmacist Interventions in Adverse Event Management During Drug Therapy for Metastatic Renal Cell Carcinoma: A Cross-Sectional Survey in Japan.

Perceptions and Expectations of Pharmacist Interventions in Adverse Event Management During Drug Therapy for Metastatic Renal Cell Carcinoma: A Cross-Sectional Survey in Japan.

Journal: Cancers

Published: October 14, 2025

Prognostic Implications of Postoperative Serum CYFRA Levels in Upper Tract Urothelial Carcinoma.

Prognostic Implications of Postoperative Serum CYFRA Levels in Upper Tract Urothelial Carcinoma.

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Published: September 03, 2025

Novel Approach to Pre-Exposure Prophylaxis (PrEP) of COVID-19: Development of S-892216 Long-Acting Injectable Suspension.

Novel Approach to Pre-Exposure Prophylaxis (PrEP) of COVID-19: Development of S-892216 Long-Acting Injectable Suspension.

Journal: Chemical & pharmaceutical bulletin

Published: August 12, 2025

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 29, 2025

Clinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settings.

Clinically informed intermediate reasoning enables generalizable prostate cancer prognostication through machine learning in limited settings.

Journal: NPJ digital medicine

Published: June 26, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026